Helius Med Technologies Inc Stock Price, News & Analysis

Solana Company (NASDAQ:HSDT) announced on October 10, 2025 that it has entered into agreements with Coinbase, BitGo, and Anchorage Digital to serve as custodians as it builds a SOL-focused digital-assets treasury. The company said this custody framework supports its strategy to amass and securely hold SOL while pursuing institutional security and transparency.

The release highlights Solana network metrics (about 3,500 transactions per second, ~3.7 million daily active wallets, and over 23 billion year-to-date transactions) and notes SOL offers an approximate 7% native staking yield. The company reiterated forward-looking risks including SOL price volatility and regulatory uncertainty.

Solana Company (NASDAQ:HSDT) announced continued accumulation of Solana (SOL) tokens as part of its digital asset treasury strategy. The company now holds over 2.2 million SOL and in excess of $15 million cash. Valued at $232.50 per SOL as of Oct 6, 2025 12:00AM ET, HSDT's combined SOL and cash holdings exceed $525 million, surpassing gross proceeds from its initial private placement that closed on September 18, 2025 in under three weeks.

The release highlights Solana network metrics cited by the company: ~3,500 transactions per second, ~3.7 million daily active wallets, and > 23 billion transactions year-to-date. SOL staking yield is noted at ~7%. The company states it will continue neurotech and medical device development alongside long-term SOL custody.

Helius Medical Technologies (NASDAQ:HSDT) announced a strategic corporate name change to Solana Company, while maintaining its HSDT ticker symbol. The company has entered into a non-binding letter of intent with the Solana Foundation, committing to "Solana By Design" terms which include conducting all on-chain activity on Solana (SOL).

The company plans to utilize its recent $500 million PIPE financing to further its digital asset treasury strategy. The agreement includes institutional partnership referrals, joint initiatives, and an option to purchase SOL tokens at a discount. Solana's network currently processes over 3,500 transactions per second, averages 3.7 million daily active wallets, and has surpassed 23 billion transactions year-to-date, offering a 7% native staking yield.

Helius Medical Technologies (NASDAQ: HSDT) has submitted a 510(k) application to the FDA for its PoNS (Portable Neuromodulation Stimulator) device, seeking label expansion for treating gait and balance deficit in chronic stroke patients. The submission, filed under FDA Breakthrough Device Designation, is supported by the Stroke Registrational Program (SRP) data.

The clinical trials, involving 159 chronic stroke survivors across 10 sites, demonstrated that PoNS Therapy combined with physical therapy achieved a clinically meaningful improvement of over 5 points in the Functional Gait Assessment (FGA), compared to less than 4 points in the control group. The treatment effect was maintained for at least 12 weeks post-therapy, with 89.7% of subjects meeting durability goals. The device proved safe with no treatment-related serious adverse events.

Helius Medical Technologies (NASDAQ:HSDT) has initiated its digital asset treasury strategy by acquiring 760,190 SOL tokens at an average cost of $231 per token. The company maintains over $335 million in cash reserves for future SOL purchases, demonstrating its commitment to the Solana ecosystem.

Solana's blockchain processes over 3,500 transactions per second and serves approximately 3.7 million daily active wallets, with more than 23 billion transactions year to date. The network offers a ~7% native staking yield. HSDT plans to continue supporting both its SOL holdings strategy and its existing neurotech and medical device operations.

Helius Medical Technologies (NASDAQ:HSDT) has successfully closed a private placement offering, raising over $500 million with potential to reach $1.25 billion through warrant exercises. The offering includes common stock and stapled warrants at $6.881 per share, with warrants exercisable at $10.134 for three years.

Led by Pantera Capital and Summer Capital, the company will implement a digital asset treasury strategy focused on acquiring SOL, Solana's native cryptocurrency. The company appointed Joseph Chee as Executive Chairman and brought in key strategic advisors from Pantera Capital.

Solana processes over 3,500 transactions per second, averages 3.7 million daily active wallets, and offers a 7% native staking yield. HSDT aims to become the premier SOL-backed treasury vehicle, following similar models to MSTR (Bitcoin) and BMNR (Ethereum).

Helius Medical Technologies (NASDAQ:HSDT) has announced a major strategic shift with a $500+ million private investment offering to launch a SOL Treasury Company. The oversubscribed PIPE offering, led by Pantera Capital and Summer Capital, includes the sale of common stock at $6.881 and stapled warrants at $10.134, with potential to deliver over $1.25 billion including warrant exercises.

The company will use proceeds to implement a digital asset treasury strategy focused on acquiring SOL, Solana's native cryptocurrency, as its primary reserve asset. The initiative leverages Solana's position as the fastest-growing blockchain, processing 3,500+ transactions per second and offering a ~7% native staking yield.

The transaction is expected to close around September 18, 2025, with incoming leadership including Joseph Chee as Director and Executive Chairman, Cosmo Jiang as Board Observer, and Dan Morehead as Strategic Advisor.

Helius Medical Technologies (NASDAQ: HSDT) has announced positive results from its PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP), supporting an upcoming FDA submission for treating gait and balance deficits in chronic stroke patients.

The program included three clinical trials with 159 total patients across 10 clinical sites in the US and Canada. The double-blind randomized trial successfully met its primary endpoint, demonstrating statistically significant improvements in gait/balance deficits with active PoNS therapy. The studies showed minimal adverse events and good treatment tolerability.

The company plans to submit an FDA application in Q3 2025 under its current Breakthrough Device Designation, targeting a market of over 7 million stroke patients, of which approximately 80% experience balance and gait deficits.

Helius Medical Technologies (Nasdaq: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has achieved full compliance with Nasdaq's continued listing requirements. The company received formal confirmation on July 7, 2025 from the Nasdaq Hearings Panel regarding compliance with the equity requirement (Rule 5550(b)(1)).

This follows their earlier compliance confirmation with the minimum bid price requirement (Rule 5550(a)(2)) received on June 3, 2025. The company will be subject to a Mandatory Panel Monitor for one year following this notification.